KPV 5mg
Investigational support for tissue-repair research.
KPV is the C-terminal tripeptide (Lys-Pro-Val) of α-MSH, isolated and studied for its anti-inflammatory activity independent of MC1R-driven pigmentation effects. It features prominently in gut-inflammation and wound-repair research.
Proposed mechanism
KPV exerts anti-inflammatory effects through mechanisms that include suppression of NF-κB signaling. Unlike the full α-MSH peptide, KPV does not drive pigmentation — making it a "pure" anti-inflammatory research tool in melanocortin-adjacent work.
Research highlights
- C-terminal tripeptide of α-MSH
- Anti-inflammatory without pigmentation effects
- Studied in IBD, colitis, and skin-inflammation models
- Small size confers good stability and bioavailability
Research protocol notes
Reconstitute under sterile technique with bacteriostatic water. Typical volumes range from 1–3 mL depending on the target working concentration. Swirl gently — do not shake — to avoid peptide shearing.
Stacking and comparative studies
KPV is sometimes combined with BPC-157 in gut-repair research designs.
Handling and storage
Lyophilized powder is stable at ambient shipping temperatures. Once reconstituted with bacteriostatic water, store at 2–8 °C and use within 28 days. For long-term storage of unreconstituted vials, freeze at −20 °C and protect from light.
Frequently asked
How does KPV relate to melanotan compounds?
KPV is the last three residues of α-MSH. Melanotan compounds are engineered analogs of α-MSH. KPV isolates the anti-inflammatory tail without the pigmentation-driving MC1R activity.
What models has KPV been studied in?
Colitis, IBD, dermatitis, and other inflammation-driven research models.
Can it be used orally in research?
Its small size confers reasonable oral bioavailability in research, though injectable routes are also used.
Why not just use α-MSH?
α-MSH drives pigmentation via MC1R — a confounding variable in inflammation research. KPV isolates the anti-inflammatory activity.
